Deepak Agarwal, DO
Anesthesiology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 2
Offices
2 locations · Cep America - Anesthesia PC · 849 clinicians in this group
Looking this up.
Hospitals listed: Washington Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Agarwal’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$63,224
Medicare paid this office $63,224 for 221 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Anesthesia for procedure for total knee joint replacement | 66 | $17,432 | $264 |
| Anesthesia for total hip replacement | 31 | $8,940 | $279 |
| Injection of substance into lower spine canal | 84 | $5,825 | $69 |
| Injection of anesthetic agent and/or steroid into thigh nerve (femoral nerve) | 68 | $2,292 | $34 |
| Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | 17 | $2,086 | $123 |
See all 7 services
| Anesthesia for procedure for total knee joint replacement | 66 | $17,432 | $264 |
| Anesthesia for total hip replacement | 31 | $8,940 | $279 |
| Injection of substance into lower spine canal | 84 | $5,825 | $69 |
| Injection of anesthetic agent and/or steroid into thigh nerve (femoral nerve) | 68 | $2,292 | $34 |
| Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | 17 | $2,086 | $123 |
| Anesthesia for lens surgery | 14 | $1,867 | $133 |
| Injection of anesthetic agent and/or steroid into arm nerve bundle (brachial plexus) | 13 | $780 | $60 |
Who their Medicare patients are
221 Original Medicare patients in 2024. Average age 75 · Women 59% · Also on Medicaid 18% · Health risk score 1.29. At or below the middle of the specialty; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 75% · Coronary heart disease 30% · Diabetes 29% · Chronic kidney disease 28% · Atrial fibrillation 23% · Cancer 20% · Heart failure 17% · Depression 15% · Dementia 9% · COPD 8% · Stroke 7%.
The office billed $933,064, Medicare allowed $79,265 and paid $63,224; for 433 services of 61 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 221 | 433 | 75 | 1.29 | $933,064 | $63,224 |
| 2023 | 239 | 439 | 75 | 1.43 | $901,786 | $65,787 |
| 2022 | 376 | 629 | 73 | 1.60 | $1,035,181 | $72,777 |
| 2021 | 701 | 2,311 | 73 | 1.18 | $1,803,382 | $149,864 |
| 2020 | 133 | 174 | 73 | 1.52 | $124,136 | $20,523 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Anesthesia for procedure for total knee joint replacement | 68 | $18,369 | $270 |
| Anesthesia for total hip replacement | 41 | $11,667 | $285 |
| Injection of substance into lower spine canal | 102 | $7,114 | $70 |
| Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | 25 | $3,062 | $122 |
| Injection of anesthetic agent and/or steroid into thigh nerve (femoral nerve) | 74 | $2,467 | $33 |
2022: 14 services
| Anesthesia for total hip replacement | 28 | $8,213 | $283 |
| Anesthesia for procedure for total knee joint replacement | 29 | $7,810 | $269 |
| Injection of substance into lower spine canal | 39 | $2,763 | $71 |
| Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | 20 | $2,697 | $128 |
| Anesthesia for lens surgery | 18 | $2,619 | $145 |
| Anesthesia for nerve block and injection procedure, prone position | 30 | $2,451 | $82 |
| Anesthesia for procedure on small and large bowel using an endoscope | 13 | $1,826 | $140 |
| Anesthesia for other procedure on large bowel using an endoscope | 13 | $1,628 | $125 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,464 | $113 |
| Ultrasonic guidance for needle placement | 45 | $1,241 | $27 |
| Anesthesia for nerve destruction procedures on spine or spinal cord of lower back accessed through skin using imaging guidance | 13 | $1,173 | $90 |
| Injection of anesthetic agent and/or steroid into thigh nerve (femoral nerve) | 33 | $1,082 | $33 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 12 | $1,032 | $86 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $157 | $10 |
2021: 27 services
| Return visit (30+ min) | 288 | $42,774 | $104 |
| Anesthesia for nerve block and injection procedure, prone position | 126 | $15,002 | $101 |
| New patient visit (45+ min) | 64 | $8,359 | $131 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 68 | $8,294 | $112 |
| Long return visit (40+ min) | 49 | $7,971 | $150 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 24 | $4,919 | $189 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 36 | $4,616 | $110 |
| Anesthesia for closed procedure on pubic bone or pelvic joint | 47 | $4,616 | $84 |
| Anesthesia for other procedure on lower spine | 16 | $3,278 | $205 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 33 | $2,962 | $87 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 23 | $2,636 | $110 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 35 | $2,538 | $62 |
| New patient visit (45+ min) | 18 | $2,070 | $115 |
| Return visit (30+ min) | 18 | $1,689 | $84 |
| New patient visit (30+ min) | 17 | $1,646 | $97 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 24 | $1,358 | $50 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 21 | $1,353 | $62 |
| Short return visit (20+ min) | 18 | $1,298 | $68 |
| Injection of substance into middle or upper spine canal using imaging guidance | 11 | $1,089 | $91 |
| Injection of trigger points, 3 or more muscles | 16 | $1,012 | $51 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 22 | $1,011 | $44 |
| Anesthesia for nerve block and injection | 14 | $881 | $63 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 35 | $442 | $10 |
| Testing for presence of drug, read by direct observation | 27 | $329 | $12 |
| Injection, methylprednisolone acetate, 80 mg | 28 | $252 | None |
| Injection, methylprednisolone acetate, 40 mg | 19 | $93 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $14 | None |
2020: 3 services
| Return visit (30+ min) | 44 | $4,531 | $94 |
| Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | 18 | $2,703 | $135 |
| Short return visit (20+ min) | 12 | $783 | $65 |
Medicaid work
$4,135 in 2022
Medicaid paid $4,135 for 25 billed services this clinician did in 2022, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 25 | $4,135 |
| 2022 | 25 | 1 | 13 | $4,135 |
| 2021 | 425 | 4 | 69 | $72,471 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 321 | $49,096 |
| Service | 56 | $17,162 |
| Anesthesia for diagnostic or therapeutic nerve blocks and injections (when block or injection is performed by a different physician or other qualified health care professional); prone position | 35 | $3,727 |
| New patient visit (45+ min) | 13 | $2,486 |
Drugs they prescribed that Part D paid
$1,483
Pharmacies billed $1,483 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
45 generic and 0 brand-name prescriptions · $1,483 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 12 | $130 | $11 |
Year by year
| 2024 | 45 | 19 | None | 0% | $1,483 |
| 2022 | 65 | 33 | 19% (12) | None | $1,548 |
| 2021 | 568 | 240 | 31% (174) | 3% | $22,746 |
| 2020 | 156 | 72 | 15% (24) | None | $6,883 |
| 2019 | 131 | 69 | 18% (23) | 11% | $7,701 |
| 2018 | 35 | 16 | None | None | $1,703 |
| 2016 | 45 | 14 | None | 24% | $1,146 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Gabapentin | 19 | $252 | $13 |
2021: 12 drugs
| Pregabalin | 59 | $3,461 | $59 |
| Hydrocodone-Acetaminophen | 92 | $2,198 | $24 |
| Gabapentin | 121 | $1,690 | $14 |
| Diclofenac | 34 | $1,485 | $44 |
| Tizanidine | 35 | $493 | $14 |
| Duloxetine | 13 | $481 | $37 |
| Oxycodone-Acetaminophen | 23 | $444 | $19 |
| Cyclobenzaprine | 13 | $401 | $31 |
| Oxycodone | 14 | $188 | $13 |
| Meloxicam | 31 | $115 | $4 |
| Tramadol | 18 | $71 | $4 |
| Naproxen | 13 | $55 | $4 |
2020: 5 drugs
| Diclofenac | 27 | $2,301 | $85 |
| Pregabalin | 11 | $925 | $84 |
| Gabapentin | 29 | $654 | $23 |
| Tizanidine | 17 | $207 | $12 |
| Hydrocodone-Acetaminophen | 11 | $182 | $17 |
2019: 3 drugs
| Diclofenac | 33 | $2,891 | $88 |
| Gabapentin | 18 | $584 | $32 |
| Amitriptyline | 11 | $152 | $14 |
Money from drug and device companies
$24 in 2024
| 2024 | 1 | 1 | None | $24 |
| 2023 | 2 | 3 | None | $76 |
| 2022 | 7 | 9 | None | $331 |
| 2021 | 9 | 57 | None | $1,662 |
| 2020 | 2 | 10 | None | $528 |
| 2019 | 4 | 7 | $100 | $10,518 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Bridion | $24 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Meals · 2024-06-04 | Bridion | $24 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $76
| AbbVie | Botox | $62 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $14 | 1 payment
|
2022: $331
| Medtronic | Intellis Adaptivestim | $83 | 1 payment
|
| Abbott Laboratories | Proclaim | $69 | 1 payment
|
| Nevro | Omnia | $59 | 1 payment
|
| Boston Scientific | General - Kidney Stone Disease | $40 | 2 payments
|
| Abbvie | Ubrelvy | $33 | 2 payments
|
| DePuy Synthes Sales | Orthovisc | $25 | 1 payment
|
| Stryker | Multigen 2 | $22 | 1 payment
|
2021: $1,662
| Abbott Laboratories | Proclaim Ipg | $653 | 29 payments
|
| Nevro | Omnia | $525 | 14 payments
|
| Relievant Medsystems | Intracept | $132 | 2 payments
|
| Boston Scientific | General Pain Management | $104 | 4 payments
|
| Bioventus | None | $91 | 1 payment
|
| Medtronic | Mystim | $74 | 3 payments
|
| Vertos Medical | Mild Device Kit | $53 | 2 payments
|
| AbbVie | Ubrelvy | $16 | 1 payment
|
| Mindray DS USA | A Series | $15 | 1 payment
|
2020: $528
| Boston Scientific | Superion | $315 | 5 payments
|
| Medtronic USA | Intellis | $212 | 5 payments
|
2019: $10,518
| Boston Scientific | Spectra Wavewriter | $10,098 | 2 payments
|
| Medtronic USA | Intellis | $208 | 3 payments
|
| Amgen | Aimovig | $113 | 1 payment
|
| Comsort | Bridion | $100 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Saluda Medical Americas, Inc. · Ecap Study · 2021 | This clinician | $16 |
Professional record
- NPI
- 1417342981
- Licence
- CA 20A18239, CA 20A19239
- Trained
- At Still University of Health Sciences, College of Osteo Med, Kirksville, 2015
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 207L00000X (207L00000X); Student in a training program (390200000X)
- Mailing address
- 10989 Bluffside Dr Apt 3106, Studio City, CA, 91604
- NPI first listed
- 2015-04-01
- NPI last updated
- 2021-02-14
- NPI record certified
- 2021-02-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9500 Euclid Ave, Cleveland, OH, 44195